1 Understanding the performance of active surveillance selection criteria in diverse urology practices Scott R. Hawken BS*,1, Paul R. Womble MD*,1, Lindsey A. Herrel MD 1, Zaojun Ye MS 1, Susan M. Linsell MHSA 1, Patrick M. Hurley MD 2, James E. Montie MD 1, David C. Miller MD, MPH 1 for the Michigan Urological Surgery Improvement Collaborative Abstract word count: 228 Word count: 2,495 Tables: 3; Figures: 1 Department of Urology, University of Michigan, Ann Arbor, MI 1 Providence Hospital, Southfield, MI 2 *Equal contribution from authors Key words: prostate cancer, active surveillance, guidelines, quality improvement Corresponding Author: David C. Miller, MD, MPH Associate Professor Department of Urology University of Michigan NCRC Building 16, Room 108E 2800 Plymouth Road Ann Arbor, MI Phone: (734) Fax: (734)
2 Abstract Purpose: We used data from the Michigan Urological Surgery Improvement Collaborative (MUSIC) to evaluate the performance of published selection criteria for active surveillance (AS) in diverse urology practice settings. Materials and Methods: For several AS guidelines, we calculated the proportion of men meeting each set of selection criteria that actually entered AS (defined as the sensitivity of the guideline). After identifying the most sensitive guideline for the entire cohort, we compared demographic and tumor characteristics between patients meeting this guideline who entered AS and those who received initial definitive therapy. Results: Among 4,882 men with newly diagnosed prostate cancer, 18% underwent AS. When applied to the entire cohort, the sensitivity of published guidelines ranged from 49% (Toronto) to 62% (Johns Hopkins, JH). At a practice-level, the sensitivity of the JH criteria varied widely from 27% to 84% (p<0.001). Compared with men undergoing AS, patients meeting JH criteria that received definitive therapy were younger (p<0.001), more likely to have a positive family history (p=0.003), a lower PSA (p<0.001), greater number of positive cores (2 vs 1) on biopsy (p<0.001), and higher cancer volume in the positive core(s)(p=0.002). Conclusions: The sensitivity of published AS selection criteria varies widely across diverse urology practices. Among patients meeting the most stringent criteria, those who received initial definitive therapy had characteristics suggesting greater cancer risk, underscoring the nuanced clinical factors that influence treatment decisions.
3 Introduction Owing to concerns about overtreatment of men with lower-risk prostate cancer, 1 4 initial active surveillance (AS) is being used more frequently for patients with early-stage disease. 5 The potential benefits of AS include avoidance of treatment-related side effects (e.g., urinary incontinence, erectile dysfunction) by delaying or not pursuing definitive therapy; however, these benefits must be weighed against the potential risk for cancer progression. Given the growing acceptance of AS among both patients and physicians, there are now many published guidelines describing optimal selection criteria for patients to enter initial AS Although most guidelines for entry into initial AS are widely recognized, 6 13 their application and performance in clinical practice is not well characterized. One measure of interest is the sensitivity of such guidelines in the real-world setting that is, how many men that meet these selection criteria actually proceed with initial AS. While it makes sense that the most restrictive criteria would also be the most sensitive, the actual proportion of patients undergoing surveillance according to these different guidelines is not well defined for diverse urology practice settings. In addition, little is known about the factors that lead men who meet established criteria for entering surveillance to nonetheless proceed with initial local therapy. In this context, we examined the sensitivity of several published guidelines for identifying men that selected initial AS in the community and academic practices comprising the Michigan Urological Surgery Improvement Collaborative (MUSIC). In addition to comparing the sensitivity of these guidelines across MUSIC practices, we also evaluated differences in demographic characteristics, comorbidity, and cancer severity among patients meeting the most sensitive selection criteria who entered AS and those who underwent initial definitive therapy. Materials and Methods Michigan Urologic Surgery Improvement Collaborative
4 MUSIC was established in 2011 with the aim of improving the quality and cost-efficiency of prostate cancer care in the state of Michigan. 5,14 16 The collaborative now includes 42 urology practices comprising more than 90% of urologists in the state. MUSIC receives financial support from Blue Cross Blue Shield of Michigan (BCBSM), and each participating practice obtained an exemption or approval for participation from a local institutional review board. Study population and data elements For all men undergoing prostate biopsy and/or with a new prostate cancer diagnosis seen in participating practices, trained abstractors enter a standardized set of data elements into a web-based registry including, patient age, race/ethnicity, Charlson comorbidity index score (CCI), serial PSA results, clinical stage, biopsy Gleason score, number of positive cores, cancer-directed treatments, and follow-up laboratory and pathology results. Quality assurance steps for MUSIC data have been described previously. 5,14 16 The population for this analysis includes 4,883 men with newly-diagnosed prostate cancer entered into the MUSIC registry from March 2012 through June Identification of primary treatment To ensure complete and accurate data, abstractors wait 3 months from the date of prostate cancer diagnosis before entering information about cancer treatment into the MUSIC registry. In addition, explicit documentation in the medical record is required to assign a specific treatment (e.g., AS, radical prostatectomy, external beam radiation therapy, etc.). For instance, the definition of AS in MUSIC (as defined by participating urologists and provided to the data abstractors) is as follows: Active Surveillance is a slightly more structured and aggressive form of watchful waiting. It is recommended that a patient undergo a DRE and a PSA test every 3 or 6 months, depending on the patient s precise history and clinical condition, and to re-biopsy the patient yearly or every two years. The physician monitors the patient aggressively and will regularly discuss disease status with the patient so that joint decisions are
5 made about the need for actual treatment. As described by Womble et al, treatment assignment in MUSIC has been externally validated with claims data with excellent concordance. 5 Identification of AS selection criteria For this analysis, we identified several of the most prominent guidelines for selecting patients for initial AS, including those from the following institutions and organizations: Johns Hopkins (JH), 6 National Comprehensive Cancer Network (NCCN): Low Risk and Very Low Risk, 7 Memorial Sloan Kettering Cancer Center (MSKCC), 8 University of California San Francisco (UCSF), 9,10 and University of Toronto. 11,12 The selection criteria for each of these guidelines are based on routinely available clinical data, but vary according to their specific elements and definitions. Statistical Analyses We first compared clinical and pathologic characteristics of patients that entered AS and those that received other initial management. Next, we calculated the proportion of all men meeting each set of selection criteria that entered AS, as well as the associated standard Wald asymptotic 95% confidence intervals. We refer to this proportion throughout the manuscript as the sensitivity of real-world practice patterns for each guideline. The numerator is comprised of men that met each selection criteria and chose AS, and the denominator is all men that met the selection criteria. After identifying the guideline with the most sensitive selection criteria for the entire study population (i.e., for the collaborative as a whole), we then examined the variation in the sensitivity of this guideline at a practice-level for sites with greater than 10 patients meeting these criteria. We chose to examine the most sensitive guideline in order to identify the cohort of patients that the greatest number of urologists would likely agree are candidates for surveillance. Next, we used chi-square testing to examine differences in the sensitivity of this guideline across MUSIC practices.
6 Finally, for men meeting selection criteria for the most sensitive guideline, we examined differences between patients who entered AS and those who received definitive therapy. Because we were only interested in men considered eligible to receive local therapy, we excluded from this analysis 47 patients managed with watchful waiting and 4 patients managed with androgen deprivation therapy. We analyzed differences in variables that are not included explicitly in the guideline selection criteria (e.g., age, race, comorbidity, practice size), as well as those that are included in the criteria but still maintain a range of clinically meaningful values after selection, such as PSA level, PSA density, number of positive biopsy cores, and greatest percentage of a core positive for cancer (GPC). Using the same variables, we also compared men meeting the most sensitive AS guidelines who received radiation versus those who underwent surgery. For each comparison, we used a two-sided t-test, Wilcoxon rank-sum test, or chi square test, where appropriate. All statistical testing was performed at the 5% significance level using SAS v9.3 (SAS Institute Inc., Cary, NC, USA). Results Table 1 presents clinical characteristics for the 4,883 men with newly diagnosed prostate cancer. Among this group, 18% (901 men) entered initial AS, 42% (2052 men) underwent surgery, 21% (1033 men) received radiation therapy, 5% (241 men) were treated with androgen deprivation therapy, 4% (188 men) selected watchful waiting, 1% (46 men) received other treatments (e.g., cryosurgical ablation), and the initial therapy was unknown for 9% (425 men) of these cases. The 9% of men with missing data for treatment were younger (mean age 63 vs 65 years, p<0.001), more likely to be African American (22% vs 15%, p<0.001), have lower clinical stage tumors (78% T1, 20% T2 vs 72% T1, 26% T2, p=0.03), and from a practice with >10 urologists (51% vs 39%, p<0.001), but were otherwise similar to those with treatment documented in the MUSIC registry.
7 Overall, men entering initial AS were older, have clinical stage T1 tumors (vs T2 or T3/4), a lower median PSA, a lower biopsy Gleason Score, fewer positive biopsy cores on biopsy, and a lower GPC (Table 1). The AS selection criteria examined in this analysis are comprised of specific combinations of routinely available clinical data, including Gleason score, PSA, PSA density, clinical T-stage, number of positive biopsy cores, and GPC. Table 2 presents a summary of the selection criteria for several published guidelines, as well as the sensitivity of each set of criteria for identifying men entering AS when applied to the entire cohort. Across all patients, the sensitivity of these criteria for identifying patients that actually entered AS ranged from a low of 48.9% (95% CI: %) for the Toronto criteria to a high of 62.4% (95% CI: %) for the Johns Hopkins criteria. The Toronto criteria identified the greatest absolute number of men entering initial AS (647 men); comparatively the NCCN: Very Low Risk criteria identified the fewest (290 men). Fourteen MUSIC practices had at least 10 patients meeting the JH selection criteria; across these sites, the sensitivity of the JH guideline for identification of patients actually receiving surveillance ranged from 27% to 84% (p<0.001, Figure 1). Among the men missing treatment data, only 10% (44 men) met the JH selection criteria. For the cohort of men meeting the JH selection criteria for initial AS and eligible for treatment (i.e., those not undergoing watchful waiting or receiving primary ADT), we compared demographics and cancer characteristics between patients that actually entered AS and those that received definitive therapy (Table 3). Compared with men undergoing initial AS, those receiving initial local therapy were younger (p<0.001), had lower PSA values (p<0.001), and were more likely to have a positive family history (p=0.003). Treated men also had evidence of greater tumor volume, as indicated by 2 (vs 1) positive cores on biopsy (p<0.001), and higher percentage of a core involved with cancer (GPC) (median 10% vs 7%, p=0.003). There were no statistically significant differences between these two groups for any of the other variables analyzed, including race and comorbidity.
8 Among the patients undergoing definitive therapy despite meeting the JH guideline, 68% and 32% underwent surgery and radiation respectively. Those that received radiation rather than surgery were older (mean age 66 vs 59 years, p<0.001), had more comorbid conditions (33% with CCI of 1, 17% with CCI 2 vs 11% with CCI of 1, 12% with CCI 2, p=0.004), and were less likely to have a family history of prostate cancer (26% vs 52%, p=0.006). Discussion: We examined data from a large number of community and academic urology practices to understand the degree to which various published AS selection criteria actually identify men who enter surveillance in real-world practice. Not unexpectedly, the sensitivity of these guidelines is variable, with those containing more stringent criteria generally capturing a greater proportion of all men meeting the criteria that actually entered AS. Conversely, more liberal criteria identified a greater absolute number of men entering AS. The most sensitive guideline overall (from Johns Hopkins) still showed significant variation in its performance at a practice-level. Among the cohort of patients meeting the JH criteria and considered eligible for local therapy, those who received definitive treatment had higher tumor volume on biopsy, as well as other characteristics favoring treatment (e.g., younger age, positive family history), that are not explicit components of current AS selection criteria. In addition, our findings suggest that when urologists counsel men about AS versus definitive treatment, they consider age and family history two relevant factors not routinely captured by AS guidelines as well small differences in the volume of cancer. Previous work exploring the implications of such differences in tumor volume has been mixed, with others demonstrating that a GPC>10%, but not the presence of one vs two positive cores at biopsy, increases the risk of adverse surgical pathology for patients with Gleason 6 prostate cancer. 17 While our findings certainly seem reassuring with respect to current practice patterns, the clinical significance of these differences in tumor volume is admittedly debatable.
9 Our overall findings are consistent with previous investigations showing that AS guidelines vary in the number of men with newly diagnosed prostate cancer that meet such selection criteria. 13 Moreover, the observed practice-level variation in sensitivity of AS guidelines is consistent with our own prior reports on AS utilization among patients with low-risk cancers 5, as well as prior studies demonstrating variation in primary treatment of localized prostate cancer by practice site and provider. 3,18 While our study identified statistically significant differences in measures of cancer risk between patients meeting JH criteria and entering surveillance versus those receiving initial local therapy, the clinical significance of these differences is modest at best. As such, it seems likely that variation in the use of AS among men meeting the stringent JH selection criteria may reflect primarily differences in patient preferences or provider perceptions and beliefs about AS that were not measured in this analysis. The optimal selection criteria for AS remain uncertain. Whereas utilizing more stringent criteria would likely identify patients with a lower risk of disease progression, it may also exclude some men that are good candidates for surveillance. Our findings also indicate that urologists in Michigan have not coalesced around a single set of selection criteria for this important initial treatment decision. Our analysis has several limitations. First, our cohort included only patients and practices in Michigan, and our findings may therefore not be generalizable to a broader population. Second, treatment data is missing for a small number of men in the cohort. Although such missing data raises concerns about selection bias, even if all 44 men missing treatment data did not receive AS, this would only decrease the sensitivity of the JH criteria to 57%; conversely, if all of these men entered initial AS, the sensitivity of the JH criteria would increase to 65%. Third, we measured neither patient preferences nor physician beliefs and perceptions about the risks of prostate cancer, treatment side effects, and comorbidities. These unmeasured factors undoubtedly play a role treatment decisions, including the selection of patients for AS. Finally, although our study examines the initial entry into AS, the effectiveness of active surveillance ultimately depends on long-term utilization with selected intervention for men with disease progression. Therefore, further study is needed to better define the outcomes of AS in this cohort.
10 Despite these limitations, our findings have important implications for both patients and providers. For patients, our findings suggest opportunities to expand the use of AS, particularly among men meeting selection criteria who prioritize preservation of urinary and/or sexual function. For providers, these data suggest that, even within a single state, there appear to be substantial differences in beliefs and perceptions around prostate cancer risk (among other factors) that affect treatment recommendations for patients with low-risk tumors. As suggested by others, differing interpretations of the evidence-base supporting the safety of AS may explain the disconnect between providers that routinely put patients on AS and those that do not. 19 It is also possible that differences in other unmeasured factors, such as financial considerations, practice setting (e.g., urban vs rural), and/or the presence and strength of any academic affiliation, are impacting treatment decisions. Moving forward, a better understanding of the entire decision making process is needed. This includes characterization of provider perceptions of risk and thresholds for treatment, how cancer risk is communicated with patients, shared decision making between patients and providers, and the degree to which differences in patient preferences drive the variation observed in this analysis. Once available, such data will provide essential context for understanding the implications of existing variation in the use of active surveillance for men with low-risk prostate cancer.
11 Acknowledgment Statement: The authors acknowledge the significant contribution of the clinical champions, urologists, administrators and data abstractors in each participating Michigan Urological Surgery Improvement Collaborative (MUSIC) practice (details around specific participating urologists and practices can be found at as well as members of the MUSIC Coordinating Center at the University of Michigan. In addition, we would like to acknowledge the support provided by David Share, MD, Tom Leyden, MBA, Rozanne Darland, BSBA, Sarah Lanivich, MBA, and the Value Partnerships program at Blue Cross Blue Shield of Michigan.
12 References: 1. Daskivich TJ, Chamie K, Kwan L, et al: Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117: Miller DC, Gruber SB, Hollenbeck BK, et al: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J. Natl. Cancer Inst. 2006; 98: Cooperberg MR, Broering JM and Carroll PR: Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 2010; 28: Jacobs BL, Zhang Y, Skolarus TA., et al: Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff. 2012; 31: Womble PR, Montie JE, Ye Z, et al: Contemporary Use of Initial Active Surveillance Among Men in Michigan with Low-risk Prostate Cancer. Eur. Urol. 2015; 67: Tosoian JJ, Trock BJ, Landis P, et al: Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J. Clin. Oncol. 2011; 29: National Comprehensive Cancer Institute (NCCN): Prostate Cancer (1.2015). Available at Accessed October Berglund RK, Masterson TA, Vora KC, et al: Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J. Urol. 2008; 180: Welty CJ, Cowan JE, Nguyen H, et al: Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate Cancer. J. Urol. 2014: Dall Era MA, Konety BR, Cowan JE, et al: Active Surveillance for the Management of Prostate Cancer in a Contemporary Cohort. Cancer 2008; 112: Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 2010; 28: Klotz L: Active surveillance for prostate cancer: for whom? J. Clin. Oncol. 2005; 23: Dall Era M a, Albertsen PC, Bangma C, et al: Active surveillance for prostate cancer: a systematic review of the literature. Eur. Urol. 2012; 62: Womble PR, Dixon MW, Linsell SM, et al: Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative. J. Urol. 2014; 191:
13 15. Riedinger CB, Womble PR, Linsell SM, et al: Variation in prostate cancer detection rates in a statewide quality improvement collaborative. J. Urol. 2014; 192: Merdan S, Womble PR, Miller DC, et al: Toward Better Use of Bone Scans Among Men With Early-stage Prostate Cancer. Urology 2014; 84: Katz MH, Shikanov S, Sun M, et al: Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. J. Endourol. 2011; 25: Hoffman KE, Niu J, Shen Y, et al: Physician Variation in Management of Low-Risk Prostate Cancer. JAMA Intern. Med. 2014; 174: Kim SP, Gross CP, Nguyen PL, et al: Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med. Care 2014; 52:
14 Table 1. Characteristics of patients undergoing initial AS versus other management strategies Variable Patients entering Patients receiving initial AS other treatments p-value Age Mean (median) 65 (66) 65 (65) Range Race, n (%) Caucasian 670 (84) 2589 (82) African American 98 (12) 460 (15) 0.1 Other 29 (4) 88 (3) Charlson Comorbidity Index score, n (%) (68) 2282 (65) (16) 697 (20) (16) 526 (15) Clinical Stage, n (%) T1 791 (88) 2404 (68) T2 104 (12) 1050 (30) <0.001 T3/4 0 (0) 88 (2) PSA level, ng/ml Median <0.001 Biopsy Gleason Score sum, n (%) (81) 796 (23) (15) 1375 (39) (2) 585 (17) < (1) 732 (21) Positive cores, n Mean (median) 1.9 (1) 4.6 (4) Range <0.001 GPC, % Mean (median) 17.3 (10) 48.1 (46) Range <0.001 GPC: Greatest Percentage Positive of a Biopsy Core.
15 Table 2. Sensitivity of published Active Surveillance selection criteria among men in Michigan with newlydiagnosed prostate cancer Selection Criteria Patients Meeting Sensitivity Guideline Gleason PSA Positive GPC Selection Criteria (95% CI) PSA T-Stage Score Density Cores (%) (n) JH 6 -- < 0.15 ct1c ( ) NCCN: Very Low Risk 6 < 10 < 0.15 ct1c ( ) MSKCC 6 < ct2a 3 < ( ) UCSF ct2 33% ( ) NCCN: Low Risk 6 < ct2a ( ) Toronto 6 < ( ) GPC: Greatest Percentage Positive of a Biopsy Core, JH: Johns Hopkins, NCCN: National Comprehensive Cancer Institute, MSKCC: Memorial Sloan Kettering Cancer Center, UCSF: University of California San Francisco.
16 Table 3. Comparison of patients meeting JH Criteria that received initial AS versus definitive local therapy Characteristic Entry Criteria Met / Entered AS Entry Criteria Met / Local therapy Total Age PSA level, ng/ml # of Positive Cores GPC Family History Mean (median) 64 (65) 61 (62) Range p-value <0.001 Median < (75%) 76 (58%) 2 77 (25%) 56 (42%) <0.001 Median (range) 7 (1-50) 10 (1-50) Positive 82 (28%) 53 (44%) 0.003
17 Figure 1. Variation in sensitivity of the Johns Hopkins selection criteria for identifying men on active surveillance across MUSIC practices.
18 Figure Legend Figure 1. Sensitivity of the Johns Hopkins (JH) guideline in practices with greater than 10 patients meeting the selection criteria. The overall sensitivity of the guideline was 62.4%. The variability among practices was statistically significant (p < 0.001).
20 Key of Definitions for Abbreviations: AS: Active Surveillance BCBSM: Blue Cross Blue Shield of Michigan CCI: Charlson comorbidity index score GPC: Greatest percentage of a biopsy core involved with cancer JH: John Hopkins MSKCC: Memorial Sloan Kettering Cancer Center MUSIC: Michigan Urological Surgery Improvement Collaborative NCCN: National Comprehensive Cancer Network UCSF: University of California San Francisco
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to
Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER DILEMMA Thomas J Stormont MD January 2012 http://www.youtube.com/watch?v=8jd 7bAHVp0A&feature=related related INTRODUCTION A government health panel (the
Annals of Oncology Advance Access published February 22, 2014 1 Intensity-Modulated Radiation Therapy Leads to Survival Benefit Only in Patients with High-Risk Prostate Cancer: a Population-Based Study
Treatment Options for Localized Prostate Cancer RAVINDER MOHAN, MD, PhD, and PAUL F. SCHELLHAMMER, MD Eastern Virginia Medical School, Norfolk, Virginia In the United States, more than 90 percent of prostate
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
Quality of Life After Radical Prostatectomy Bernard H. Bochner, MD FACS Attending Surgeon, Urology Service Vice Chairman, Department of Surgery Memorial Sloan-Kettering Cancer Center Quality of Life After
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15. CLINICAL CASE The Debate Over Prostate Cancer Screening Guidelines Commentary by Karen E. Hoffman,
Modeling Drivers of Cost and Benefit for Policy Development in Cancer Harms? Benefits? Costs? Ruth Etzioni Fred Hutchinson Cancer Research Center Seattle, Washington The USPSTF recommends against routine
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
The 4Kscore blood test for risk of aggressive prostate cancer Early detection of aggressive prostate cancer Challenges Serum PSA has a high false positive rate Over 1 million prostate biopsies performed
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS
Local Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36153
SRO Tutorial: Prostate Cancer Treatment Options May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible,
Prostate Cancer: Screening Update Middlesex Hospital Cancer Center Comprehensive Prostate Cancer Program Edward G. Myer, M.D. Middlesex Urology, P.C. October 15, 2015 Middlesex Hospital Cancer Center Comprehensive
Prostate Cancer PSA Controversy and Emergence of Active Surveillance Christopher J. Kane MD Professor of Surgery, Chief of Urology C Lowell and JoEllen Parsons Chair in Urology Disclosures NCI Kidney Cancer
DRAFT: Advice from Dr John Childs MoH advisor Summary of Harms from Screening and Treatment for Prostate Cancer There are minimal risks directly attributable to PSA testing or transrectal ultrasound (TRUS)
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy
Prostate Cancer Screening Bruce L. Houghton, MD Associate Professor of Medicine Division of General Medicine Department of Internal Medicine Creighton University School of Medicine http://en.wikipedia.org/wiki/image:prostatelead.jpg
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
United States Government Accountability Office Report to Congressional Requesters July 2013 MEDICARE Higher Use of Costly Prostate Cancer Treatment by Providers Who Self- Refer Warrants Scrutiny GAO-13-525
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
Clinical Practice Guidelines Prostate Cancer Screening CareMore Quality Management CareMore Health System adopts Clinical Practice Guidelines for the purpose of improving health care and reducing unnecessary
Prostate Cancer Patients Report on Benefits of Proton Therapy Dobson DaVanzo & Associates, LLC Vienna, VA 703.260.1760 www.dobsondavanzo.com Prostate Cancer Patients Report on Benefits of Proton Therapy
PROSTATE CANCER UPDATE DISCLOSURES I, BRUCE WAYNE PORTERFIELD HAVE NOTHING TO DISCLOSE. OBJECTIVES Epidemiology Early detection and screening Review of clinical disease states Treatment options by disease
The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California
Management of Localized Prostate Cancer Surgery James A. Eastham, MD Chief, Urology Service Memorial lsloan Kettering Cancer Center Treatment Options 1. Active surveillance/watchful waiting 2. Focal therapy
PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based
Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Case #1 A 55 yo white man with well-controlled hypertension presents for his annual
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
Prostate Cancer Definition Prostate cancer is cancer that starts in the prostate gland. The prostate is a small, walnut-sized structure that makes up part of a man's reproductive system. It wraps around
Coding for Prostate Cancer Tracy L. Burney, M.D. Health First Physicians Urology September 19, 2012 Prostate Cancer Basics What is the Prostate and What Does it do? Walnut sized organ found only in men.
Selecting a /(searching for) (feasible) research project and (appropriate) mentor Pathways to Careers in Clinical and Translational Research (PACCTR) Curriculum Core Plan What is clinical and translational
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
Prostate Cancer Anatomy Paul A. Godley, MD, PhD Cancer Incidence, Males Prostate Cancer Epidemiology 24 Estimated New Cancer Cases Melanoma 29,9 Oral 18,55 Stomach 13,4 Leukemias 19,2 Kidney 22,8 Lymphomas
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
Prostate Cancer Screening Dr. J. McCracken, Urologist USPSTF Lifetime risk for diagnosis currently estimated at 15.9% Llifetime risk of dying of prostate cancer is 2.8% Seventy percent of deaths due to
Prostate-Specific Antigen Based Screening: Controversy and Guidelines Eric H. Kim and Gerald L. Andriole Institutional Address: Washington University School of Medicine 4960 Children's Place Campus Box
1 Treatment Routes in Prostate Cancer Urological Cancers SSCRG Introduction To better understand outcome measures, it is necessary to analyse what treatment pathway a patient has followed after diagnosis.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Prolaris Prostate Cancer Genomic Assay (DL35629) Please note: This is a Proposed/Draft policy. Proposed/Draft LCDs are works in progress that are
Prostate Cancer Screening: What We ve Learned and Where we should go Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University
Proton Therapy for Prostate Cancer: Your Questions, Our Answers. When you re looking for the right treatment for your prostate cancer, nothing s more important than accurate information. Read on, and learn
DOI: 10.1093/jnci/djr028 ARTICLE JNCI djr028 MA JOURNAL NAME Art. No. CE Code The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: firstname.lastname@example.org.
Assessing California s Prostate Cancer Resources for the Working Poor in Urban and Rural California Sarah E. Connor, MPH, CHES Mark S. Litwin, MD, MPH Laura Baybridge APHA 2007 This research was supported
Clinical Practice Guidelines and Shared Decision Making for Prostate Cancer Screening Dr. Roger Luckmann Associate Professor Family Medicine and Community Health UMass Medical School Disclosures I have
www.medscape.com Update on Prostate Cancer Screening Guidelines Christine Gonzalez, PharmD, CHHC US Pharmacist Abstract and Introduction Introduction In the United States, prostate cancer is the most common
PROSTATE CANCER 1. Guidelines for Screening Risk Factors Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American High-risk men: Family history of prostate
special article Use of Intensity-Modulated Radiation Therapy for Prostate Cancer Jean M. Mitchell, Ph.D. ABSTRACT BACKGROUND Some urology groups have integrated intensity-modulated radiation therapy (IMRT),
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; email@example.com (2) Steven